Effects of the NMDA antagonist ketamine on task-switching performance: Evidence for specific impairments of executive control

Neuropsychopharmacology

Volumn 31, Issue 8, 2006, Pages 1675-1681

  Stoet, Gijsbert ^a   Snyder, Lawrence H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal behavior; Cognition; Ketamine; Monkeys; NMDA; Schizophrenia

Indexed keywords

GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ACCURACY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; EXPOSURE; MACACA; MALE; MENTAL DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM; TASK PERFORMANCE; VISUAL INFORMATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MACACA MULATTA; MALE; PSYCHOMOTOR PERFORMANCE; REACTION TIME; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 33746321251     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300930     Document Type: Article

References (46)

1. Abramczyk RR, Jordan DE, Hegel M (1983). 'Reverse' Stroop effect in the performance of schizophrenics. Percept Motor Skills 56: 99-106.
2. Adler C, Malhotra A, Elman I, Goldberg T, Egan M, Pickar D et al (1999). Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156: 1646-1649.
3. Atkinson RC, Shiffrin RM (1968). Human memory: a proposed system and its control processes. In: Spence KW, Spence JT (eds). The Psychology of Learning and Motivation. Academic Press: New York. pp 89-195.
4. Avila MT, Weiler MA, Lahti AC, Tamminga CA, Thaker GK (2002). Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am J Psychiatry 159: 1490-1496.
5. Barch DM, Carter CS, Perlstein W, Baird J, Cohen D, Schooler N (1999). Increased stroop facilitation effects in schizophrenia are not due to increased automatic spreading activation. Schizophr Res 39: 51-64.
6. Barton JJ, Cherkasova MV, Lindgren K, Goff DC, Intriligator JM, Manoach DS (2002). Antisaccades and task switching: studies of control processes in saccadic function in normal subjects and schizophrenic patients. Ann NY Acad Sci 956: 250-263.
7. Butterfield EC, Belmond JM (1977). Assessing and improving executive cognitive functions of mentally retarded people. In: Bialar I, Sternlicht M (eds). Psychological Issues in Mental Retardation. Psychological Dimensions: New York. pp 277-318.
8. Carlsson A, Lindqvist M (1963). Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140-144.
9. Condy C, Wattiez N, Rivaud-Pechoux S, Gaymard B (2005). Ketamine-induced distractibility: an oculomotor study in monkeys. Biol Psychiatry 57: 366-372.
10. Cools R, Brouwer WH, de Jong R, Slooff C (2000). Flexibility, inhibition, and planning: frontal dysfunctioning in schizophrenia. Brain Cogn 43: 108-112.
11. Evans JJ, Chua SE, McKenna PJ, Wilson BA (1997). Assessment of the dysexecutive syndrome in schizophrenia. Psychol Med 27: 635-646.
12. Everett J, Laplante L, Thomas J (1989). The selective attention deficit in schizophrenia: limited resources or cognitive fatigue? J Nerv Ment Dis 177: 735-738.
13. Fischer B, Weber H (1992). Characteristics of 'anti' saccades in man. Experimental Brain Res 89: 415-424.
14. Franke P, Maier W, Hain C, Klingler T (1992). Wisconsin Card Sorting Test: an indicator of vulnerability to schizophrenia. Schizophr Res 6: 243-249.
15. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC (1985). Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol 5: 70-77.
16. Goff DC (2000). Glutamate receptors in schizophrenia and antipsychotic drugs. In: Lidow MS (ed). Neurotransmitter Receptors in Actions of Antipsychotic Medications. CRC Press: New York, NY. pp 121-136.
17. Goldman RS, Band LM, Tomkins BNA (1992). Effect of instructional cues on schizophrenic patients' performance on the Wisconsin Card Sorting Test. Am J Psychiatry 149: 1718-1722.
18. Hepp HH, Maier S, Hermle L, Spitzer M (1996). The Stroop effect in schizophrenic patients. Schizophr Res 22: 187-195.
19. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K et al (1999). Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283: 70-74.
20. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL et al (2000). Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48: 627-640.
21. Kravariti E, Dixon T, Frith C, Murray R, McGuire P (2005). Association of symptoms and executive function in schizophrenia and bipolar disorder. Schizophr Res 74: 221-231.
22. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC et al (2000). Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 47: 137-143.
23. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman R, Charney DS et al (1999). NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies for neuropsychiatric disorders. Harv Rev of Psychiatry 7: 125-133.
24. Laruelle M, Kegeles LS, Abi-Dargham A (2003). Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad Sci 1003: 138-158.
25. Levy DL, Mendell NR, LaVancher CA, Brownstein J, Krastoshevsky O, Teraspulsky L et al (1998). Disinhibition in antisaccade performance in schizophrenia. In: Lenzenweger MF, Dworkin RH (eds). Origins and Development of Schizophrenia. American Psychological Association: Washington, DC. pp 185-210.
26. Li CR (2004). Do schizophrenia patients make more perseverative than non-perseverative errors on the Wisconsin Card Sorting Test? A meta-analytic study. Psychiatry Res 129: 179-190.
27. Manoach DS, Lindgren KA, Cherkasova MV, Goff DC, Halpern EF, Intriligator J et al (2002). Schizophrenic subjects show deficient inhibition but intact task switching on saccadic tasks. Biol Psychiatry 51: 816-826.
28. Meiran N, Levine J, Meiran N, Henik A (2000). Task set switching in schizophrenia. Neuropsychology 14: 471-482.
29. Monsell S (2003). Task switching. Trends Cogn Sci 7: 134-140.
30. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV (2004). Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29: 208-218.
31. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33: 523-533.
32. Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999). Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37: 251-270.
33. Radant A, Bowdle T, Cowley D, Kharasch E, Roy-Byrne P (1998). Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19: 434-444.
34. Reuter B, Kathmann N (2004). Using saccade tasks as a tool to analyze executive dysfunctions in schizophrenia. Acta Psychol (Amst) 115: 255-269.
35. Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA (2005). Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 30: 633-639.
36. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, Kaufer DI et al (2002). Executive control function: a review of its promise and challenges for clinical research, a report from the committee on research of the american neuropsychiatric association. J Neuropsychiatry Clin Neurosci 14: 377-405.
37. Semkovska M, Bedard MA, Godbout L, Limoge F, Stip E (2004). Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res 69: 289-300.
38. Shiigi Y, Casey DE (1999). Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates. Psychopharmacology 146: 67-72.
39. Stoet G, Snyder LH (2003a). Executive control and task-switching in monkeys. Neuropsychologia 41: 1357-1364.
40. Stoet G, Snyder LH (2003b). Task preparation in macaque monkeys (Macaca mulatta). Anim Cogn 6: 121-130.
41. Stoet G, Snyder LH (2004). Single neurons in posterior parietal cortex (PPC) of monkeys encode cognitive set. Neuron 42: 1003-1012.
42. Stroop JR (1935). Studies of interference in serial verbal reactions. J Exp Psychol 18: 643-662.
43. Taffe MA, Davis SA, Gutierrez T, Gold LH (2002). Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug Alcohol Depend 68: 175-187.
44. Turken AU, Vuilleumier P, Mathalon DH, Swick D, Ford JM (2003). Are impairments of action monitoring and executive control true dissociative dysfunctions in patients with schizophrenia? Am J Psychiatry 160: 1881-1883.
45. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000). Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57: 1139-1147.
46. Wysocki JJ, Sweet JI (1985). Identification of brain damaged, schizophrenic, and normal medical patients using a brief neuropsychological screening battery. Int J Clin Neuropsychol 7: 40-44.